Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards person-centered pain management in dementia: usability of a digital medical device in Portuguese residential care facilities.

Frontiers in health services·2026
Same author

Digital decoding of the multidimensional pain experience in people living with dementia.

Age and ageing·2026
Same author

Barriers and strategies for pain management in non-verbal people with dementia in residential care facilities: protocol for an e-Delphi study.

BMJ open·2025
Same author

A cross-sectional study of pharmacy academics' perspectives on the scope of minor ailments in Indonesia and implications for pharmacy education.

The International journal of pharmacy practice·2025
Same author

A narrative review of pharmacy workforce challenges in Indonesia.

Human resources for health·2025
Same author

Association between long-term use of calcium channel blockers (CCB) and the risk of breast cancer: a retrospective longitudinal observational study protocol.

BMJ open·2024

Related Experiment Video

Updated: Jul 5, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Amiodarone-induced pulmonary toxicity.

Desak Ketut Ernawati1, Leanne Stafford, Jeffery David Hughes

  • 1Laboratorium of Pharmacy, School of Medicine, Udayana University, Jl PB Sudirman Denpasar, Bali, Indonesia. desak_ke@yahoo.com

British Journal of Clinical Pharmacology
|May 8, 2008
PubMed
Summary

Older age and longer amiodarone therapy duration are key risk factors for amiodarone-induced pulmonary toxicity (AIPT). Targeted monitoring of these patients is recommended for early detection and management of this serious adverse drug reaction.

More Related Videos

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Related Experiment Videos

Last Updated: Jul 5, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Area of Science:

  • Pulmonology
  • Pharmacology
  • Clinical Medicine

Background:

  • Amiodarone is a widely used antiarrhythmic drug.
  • Amiodarone-induced pulmonary toxicity (AIPT) is a serious adverse effect.
  • Several factors have been hypothesized to increase AIPT risk.

Purpose of the Study:

  • To identify and confirm risk factors for AIPT.
  • To compare risk factors in a tertiary hospital cohort with previously identified factors.

Main Methods:

  • Phase I: Logistic regression analysis of amiodarone adverse reaction reports from Australian and US drug agencies.
  • Phase II: Retrospective review of medical records for AIPT cases at Fremantle Hospital and Health Service (2000-2005).
  • Comparison of risk factors between Phase I and Phase II cohorts.

Main Results:

  • 237 AIPT cases identified from agency data.
  • Highest risk associated with age > 60 years and amiodarone therapy duration of 6-12 months (OR 18.28).
  • Seven AIPT cases in the FHHS cohort exhibited high-risk profiles based on age and therapy duration.

Conclusions:

  • Only patient age and amiodarone therapy duration were confirmed as significant risk factors for AIPT.
  • Findings contradict some previous hypotheses regarding AIPT risk factors.
  • Targeted monitoring of high-risk patients may aid early AIPT identification and management.